Cartesian Therapeutics Inc’s recent filing unveils that its Chief Technology Officer Kurtoglu Metin unloaded Company’s shares for reported $0.27 million on Dec 09 ’24. In the deal valued at $25.50 per share,10,763 shares were sold. As a result of this transaction, Kurtoglu Metin now holds 51,033 shares worth roughly $0.97 million.
Then, Kurtoglu Metin sold 2,901 shares, generating $70,640 in total proceeds. Upon selling the shares at $24.35, the Chief Technology Officer now owns 51,033 shares.
Before that, METIN KURTOGLU bought 2,901 shares. Cartesian Therapeutics Inc shares valued at $70,640 were divested by the Officer at a price of $24.35 per share.
BTIG Research initiated its Cartesian Therapeutics Inc [RNAC] rating to a Buy in a research note published on December 19, 2024; the price target was $42. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early August with a ‘”a Buy”‘ rating. Oppenheimer also remained covering RNAC and has decreased its forecast on July 02, 2024 with a “Perform” recommendation from previously “an Outperform” rating. Oppenheimer started covering the stock on June 04, 2024. It rated RNAC as “an Outperform”.
Price Performance Review of RNAC
On Friday, Cartesian Therapeutics Inc [NASDAQ:RNAC] saw its stock fall -1.30% to $19.02. Over the last five days, the stock has gained 1.79%. Cartesian Therapeutics Inc shares have fallen nearly -8.04% since the year began. Nevertheless, the stocks have fallen -6.30% over the past one year. While a 52-week high of $41.87 was reached on 06/06/24, a 52-week low of $11.66 was recorded on 04/08/24. SMA at 50 days reached $20.18, while 200 days put it at $19.88.
Levels Of Support And Resistance For RNAC Stock
The 24-hour chart illustrates a support level at 18.54, which if violated will result in even more drops to 18.06. On the upside, there is a resistance level at 19.69. A further resistance level may holdings at 20.36. The Relative Strength Index (RSI) on the 14-day chart is 47.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.48, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.33%. Stochastics %K at 16.84% indicates the stock is a buying.
How much short interest is there in Cartesian Therapeutics Inc?
A steep rise in short interest was recorded in Cartesian Therapeutics Inc stocks on 2024-11-29, dropping by 97638.0 shares to a total of 1.83 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 1.93 million shares. There was a decline of -5.33%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 24, 2024 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
